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Objective: Many high-risk patients with severe symptomatic aortic stenosis are not referred for surgical aortic
valve replacement. Although this patient population remains ill-defined, many of these patients are now being
referred for percutaneous aortic valve replacement. We sought to define the characteristics and outcomes of
patients referred for percutaneous aortic valve replacement.
Methods: Between February 2006 and March 2007, 92 patients were screened for percutaneous aortic valve
replacement. Clinical and echocardiographic characteristics of patients undergoing surgical aortic valve replace-
ment, percutaneous aortic valve replacement, balloon aortic valvuloplasty, or no intervention were compared. The
primary end point was all-cause mortality.
Results: Nineteen patients underwent successful surgical aortic valve replacement, 18 patients underwent percu-
taneous aortic valve replacement, and 36 patients had no intervention. Thirty patients underwent balloon aortic
valvuloplasty, and of these, 8 patients were bridged to percutaneous aortic valve replacement and 3 were bridged
to surgical aortic valve replacement. Of the remaining 19 patients undergoing balloon aortic valvuloplasty, bridg-
ing to percutaneous aortic valve replacement could not be accomplished because of death (n ¼ 9 [47%)],
exclusion from the percutaneous aortic valve replacement protocol (n ¼ 6 [32%]), and some patients improved
after balloon aortic valvuloplasty and declined percutaneous aortic valve replacement (n ¼ 4 [21%]). The most
common reasons for no intervention included death while awaiting definitive treatment (n ¼ 10 [28%]), patient
uninterested in percutaneous aortic valve replacement (n¼ 10 [28%]), and questionable severity of symptoms or
aortic stenosis (n ¼ 9 [25%]). Patients not undergoing aortic valve replacement had higher mortality compared
with those undergoing aortic valve replacement (44% vs 14%) over a mean duration of 220 days.
Conclusion: Symptomatic patients with severe aortic stenosis have high mortality if timely aortic valve replace-
ment is not feasible. Twenty percent of the patients referred for percutaneous aortic valve replacement underwent
surgical aortic valve replacement with good outcome. Patients undergoing balloon aortic valvuloplasty alone or
no intervention had unfavorable outcomes.
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Aortic stenosis (AS) is the most common valvular lesion in
the aging population, with a prevalence of 4.6% in adults
more than 75 years of age.1-3 Surgical aortic valve replace-
ment (SAVR) is the recommended treatment for symptom-
atic patients.4 After the onset of symptoms, average
survival can be as low as 1 to 3 years without SAVR.4-8
However, many patients with severe symptomatic AS do
not undergo surgical intervention for various reasons.
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ence of comorbidities or patient preference, and others are
deemed inoperable by the surgeon because of the presence
of coexisting illnesses. This is particularly the case for the
elderly. In the Euro Heart Survey on valvular heart disease,
33% of patients with severe symptomatic AS did not un-
dergo surgical intervention.9 Other studies have similarly
shown that 27% to 41% patients with severe symptomatic
AS do not undergo SAVR.8,10-12
These studies included patients who were identified by
means of screening echocardiographic laboratory databases
for severe AS or those who were referred for SAVR. It is
possible that there are other patients who do not come to
the attention of cardiologists or tertiary care centers for var-
ious reasons. With the advent of percutaneous aortic valve
replacement (PAVR),13-18 many of these patients are now
being referred for this ‘‘less invasive’’ investigational proce-
dure. This provides a unique opportunity to characterize the
unmet need for aortic valve replacement. Accordingly, we
studied the characteristics and outcomes of patients referred
for PAVR.rgery c June 2009




AS ¼ aortic stenosis
BAV ¼ balloon aortic valvuloplasty
MR ¼ mitral regurgitation
PAVR ¼ percutaneous aortic valve
replacement
REVIVAL ¼ Transcatheter Endovascular
Implantation of Valves
SAVR ¼ surgical aortic valve replacement
STS ¼ Society of Thoracic Surgeons
MATERIALS AND METHODS
All patients screened at our institution for PAVR have been included in
a prospective registry. These were patients who were thought to be at very
high risk for SAVR by the referring doctors. Ninety-two consecutive patients
screened for PAVR fromFebruary 2006 throughMarch 2007were included in
this prospective cohort study. At baseline, all patients underwent a structured
assessment, including history and physical examination, electrocardiogram,
Doppler echocardiography, and coronary and peripheral angiography. All pa-
tients with severe AS, irrespective of the previous recommendations from re-
ferring institutions, were independently evaluated by 2 surgeons for aortic
valve replacement. The decision to perform either SAVR or PAVR was
made by a multidisciplinary team consisting of cardiologists with expertise
in clinical, interventional, and imagingfields; cardiothoracic surgeons; andcar-
diacanesthesiologistswith extensive experience inSAVRinhigh-risk patients.
The decision-making process was a complex interplay of clinical presentation,
physical examination, andvarious diagnostic tests, alongwith consideration of
social situation (Figure 1). If patients were not candidates for cardiac surgery,
theywere evaluated for theTranscatheterEndovascular ImplantationofValves
(REVIVAL) trial. TheSocietyofThoracicSurgeons (STS)scorewasprimarily
used to make this determination; however, factors that are not captured in the
STS score, such as prior chest radiation, porcelain aorta, anatomic issues (eg,
graftsor cardiac chambers adherent to sternumand lackof sternum), and severe
debilitation, were also taken into account to determine the candidacy for
SAVR. Under the REVIVAL study protocol, PAVR was performed only in
patients who were deemed inoperable or had an estimated operative mortality
of greater than 15%, as per the inclusion criteria. Patients who were excluded
from PAVR for reasons such as thrombocytopenia (n¼ 2), cancer (n¼ 2), se-
vere left ventricular dysfunctionwith an ejection fraction of less than 20% (n¼
1), and age of less than70 years (n¼ 1) underwent balloon aortic valvuloplasty
(BAV). Patients whowere neither accepted for cardiac surgery nor for the RE-
VIVAL trial were clinically evaluated and medically managed. BAV was of-
fered to those patients who could be considered for surgical intervention in the
future if their general status improvedand to thosewho could not leave the hos-
pital because of AS-related congestive heart failure. All patients who under-
went BAV were re-evaluated for SAVR. For analysis, patients who were
bridged to SAVR or PAVR after BAVwere included in the respective groups
(SAVR or PAVR). Clinical and echocardiographic characteristics were com-
pared among these patients based on the modality of treatment. The primary
end point for outcome was all-cause mortality. Mortality was assessed by que-
rying theSocial SecurityDeath Index or bydirectly referring to patient charts in
case of in-hospitalmortality. Length of hospital stay and postoperative compli-
cations were determined by means of chart review. The institutional review
board waived requirements for informed consent.
Continuous data are presented as means standard deviation. Student’s
t test was used to compare mean values for continuous variables. Multiple
groups were compared by using 1-way analysis of variance. Post-hoc anal-
ysis was performed with the Newman–Keuls test. The c2 or Fisher’s exact
test was used to find significant associations between categorical variables.The Journal of Thoracic and CAll tests were 2-tailed. Statistica 6.1 (Statsoft, Inc, Tulsa, Okla) software
was used for analysis.
RESULTS
Patient Characteristics
Baseline characteristics of the 4 groups are shown in Ta-
ble 1. Of the 92 patients screened, 53 (58%) were 80 years or
older, and 36 (39%) were 85 years or older. There were 35
(39%) patients who had at least 1 prior cardiac surgery, 30
(34%) who had previously diagnosed severe lung disease
(forced expiratory volume in 1 second 1 L or on home ox-
ygen), and 10 (11%) who had chronic kidney disease (serum
creatinine value,>2 mg/dL). There were 23 (25%) patients
with a left ventricular ejection fraction of 30% or less and 10
(11%) patients with an ejection fraction of 20% or less. Ad-
ditionally, 14 (15%) patients had severe mitral regurgitation
(MR), and 33 (36%) patients had severe pulmonary hyper-
tension (systolic pulmonary artery pressure, 50 mm Hg;
Figure 2). The mean Logistic EuroSCORE of all patients
was 26, with 51% of patients having a score of greater
than 20. The mean STS score of all patients was 12.8,
with 43% of patients having a score of 10 or greater.
Patient Management
Further information on patient management is shown in
Figure 3. Of the 92 patients who were screened for possible
PAVR, 19 (21%) underwent SAVR, and 18 (20%) under-
went PAVR. Of the patients who underwent aortic valve re-
placement, 3 were bridged to SAVR after BAV, and 8 were
bridged to PAVR after BAV. Nineteen (21%) patients could
not be bridged to aortic valve replacement after BAV. Of
these 19 patients who underwent BAV alone, 9 (47%)
died while waiting for PAVR, 4 (21%) improved after
FIGURE 1. Decision process. AVR, Aortic valve replacement; REVIVAL,
Transcatheter Endovascular Implantation of Valves; STS, Society of Tho-
racic Surgeons; BAV, balloon aortic valvuloplasty.ardiovascular Surgery c Volume 137, Number 6 1431
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DTABLE 1. Baseline patient characteristics
All patients (n ¼ 92) No intervention (n ¼ 36) SAVR (n ¼ 19) PAVR (n ¼ 18) BAV alone (n ¼ 19) P value
Clinical characteristics
Age (y) 81  7 83  8 78  7 81  6 81  8 .52
Male sex (%) 51 (55) 17 (47) 10 (53) 12 (67) 12 (63) .48
NYHA class III 54 (59%) 19 (53%) 14 (74%) 6 (33%) 15 (79%) .12
NYHA class IV 38 (41%) 17 (47%) 5 (26%) 12 (67%) 4 (21%) .07
Peripheral arterial disease 26/89 (29%) 12/34 (35%) 3/19 (16%) 6/18 (33%) 5/18 (28%) .48
Severe chronic obstructive
pulmonary disease
30/88 (34%) 8/33 (24%) 5/19 (26%) 8/18 (44%) 9/18 (50%) .18
Previous coronary artery
bypass graft surgery
35/89 (39%) 13/34 (38%) 8/19 (42%) 7/18 (39%) 7/18 (39%) .81
Creatinine (mg/dL) 1.5  1.2 1.7  1.7 1.2  0.5 1.4  0.6 1.5  0.9 .48
Porcelain aorta 8/67 (12%) 2/18 (11%) 2/15 (13%) 3/18 (17%) 1/16 (6%) .80
Additive EuroSCORE 10.8  2.8 10.8  2.8 9.6  2.1 11  3 11.7  3.2 .73
Logistic EuroSCORE 25.6  17.4 25.4  17.6 18.3 8.4 27.8  18.8 35.2  20.9 .42
STS score 12.8  9.8 12.6  9.2 9.2  6.7 11.4  7.5 17.9  13.6 .047
Follow-up (d) 218  121 179  105 266  106y 278  128y 179  122 .002
Echocardiographic characteristics
Aortic valve area (cm2) 0.6  0.2 0.7  0.2 0.6  0.1 0.6  0.1 0.6  0.1 .6
Peak gradient (mm Hg) 75  31 72  29 87  37 80  25 65  29 .11
Mean gradient (mm Hg) 43  18 41  17 51  23 46  16 37  17 .09
Mitral regurgitation 1.6  0.8 1.5  0.8 1.2  0.6 1.9  0.7* 1.8  0.9* .01
Aortic incompetence 1.3  0.8 1.3  0.8 1.4  0.8 1.2  0.8 1.3  0.6 .70
Ejection fraction (%) 46  16 48  16 49  14 46  17 38  17z .02
SAVR, Surgical aortic 90 valve replacement; PAVR, percutaneous aortic valve replacement; BAV, balloon aortic valvuloplasty;NYHA, NewYork Heart Association; STS, Society of
Thoracic Surgeons. *Patients who underwent percutaneous aortic valve replacement and those undergoing balloon aortic valvuloplasty alone had a higher degree of mitral regur-
gitation compared with those who underwent surgical aortic valve replacement. yFollow-up was longer for patients undergoing surgical or percutaneous aortic valve replacement.
zPatients who underwent balloon aortic valvuloplasty alone had lower ejection fraction compared with other groups.BAV but did not want PAVR, and 6 (32%) remained unsuit-
able for SAVR and were excluded from the PAVR study
protocol for various reasons, as mentioned in the Methods
section. Thirty-six (39%) patients did not undergo any inter-
vention. The most common reasons for no intervention in-
cluded mortality before definitive treatment because oflimitation in the number of patients who could be enrolled
for PAVR (n ¼ 10 [28%]), patients not interested in the
study (n ¼ 10 [28%]), and patients with symptoms not
clearly attributable to severe AS (n ¼ 9 [25%]).
There were no differences in the baseline clinical charac-
teristics among the 4 groups of patients: those undergoingFIGURE 2. Patient characteristics.
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echocardiographic characteristics, patients who underwent
BAV alone had lower left ventricular ejection fractions com-
pared with the other groups (38%  17% vs 49%  14%,
46% 17%, and 48% 16%, respectively; P¼ .02). Ad-
ditionally, 8 (42%) patients with ejection fractions of less
than 30% underwent BAV alone compared with 3 (16%)
patients in the SAVR, 5 (25%) in the PAVR, and 7 (19%)
in the no intervention groups. Also, patients who underwent
PAVR and those undergoing BAV alone had a higher degree
of MR compared with those who underwent SAVR
(1.9  0.7 and 1.8  0.9 vs 1.2  0.6, respectively;
P ¼ .01). Patients undergoing surgical intervention had
lower logistic EuroSCOREs compared with other patients
(18  8 vs 27  18, respectively; P ¼ .04). Patients
undergoing surgical intervention had lower STS scores com-
pared with patients undergoing BAV alone (9.2  6.7 vs
17.9  13.6, P ¼ .02).
Outcome
Further information on outcomes is available in Figure 4.
Of the 92 patients in this study, overall mortality was 32%
(29 patients), with a mean follow-up of 220 days. In-hospi-
tal/30-day mortality for the SAVR group was 0%, with total
mortality of 5% on follow-up (1 patient died 2 months after
surgical intervention from an unknown cause). In-hospital/
30-day mortality in the PAVR group was 5% (1 patient
died of renal failure and sepsis on postprocedure day 10).
The mortality in the PAVR group on follow-up was 22%
(4 patients: 1 in-hospital death, as noted above; 1 had unsuc-
cessful PAVR and died 2 months later of congestive heart
failure; 1 died after 3 months of complications from liver cir-
rhosis after refusing liver transplantation; and 1 died after 4
months from multiple myeloma diagnosed after PAVR).
Length of hospital stay and complications after SAVR and
FIGURE 3. Patient management. PAVR, Percutaneous aortic valve re-
placement; SAVR, surgical aortic valve replacement; BAV, balloon aortic
valvuloplasty; MSOF, multisystem organ failure; AI, aortic insufficiency.The Journal of Thoracic and CPAVR are shown in Table 2. Four patients in the PAVR
group had 3þMR before PAVR. Postoperatively, 3 of these
patients had 2þMR and 1 had 1þMR on follow-up.
Mortality in the BAV-only group was 47% (9 patients)
after a mean duration of 55 days after BAV. Of these pa-
tients, 1 died of severe aortic insufficiency after BAV, 1
died of cancer after 5 months, 5 died of multisystem organ
failure, and 2 experienced sudden death. In patients not un-
dergoing any intervention, 1-year mortality was 42% (15
patients). Mortality was 9% (1/11) in patients bridged to
SAVR or PAVR after BAV.
DISCUSSION
Our findings demonstrate that patients with advanced age
and comorbidities, such as renal insufficiency, lung disease,
previous cardiac surgeries, and poor left ventricular func-
tion, are being referred for PAVR. These symptomatic pa-
tients with severe AS have high mortality if SAVR or
PAVR is not performed in a timely manner. About 20%
of the patients referred for PAVR were found to be surgical
candidates and underwent AVR with no operative deaths in
an experienced center. High-risk patients who had no inter-
vention or who were not bridged to either PAVR or SAVR
after BAV had an excessive mortality rate of 44%.
FIGURE 4. Kaplan–Meier survival curve: Patients referred for percutane-
ous aortic valve replacement.
TABLE 2. Length of stay and complications
Postoperative complications SAVR (n ¼ 19) PAVR (n ¼ 18) P value
Length of stay (d) 12  4 12  6 .3
Transfusion 7 (37%) 7 (39%) .94
Stroke 0 0 1.0
Infection 2 (11%) 2 (11%) 1.0
Myocardial infarction 0 0 1.0
Prolonged ventilation 1 (5%) 1 (6%) 1.0
Nursing home 0 1 (5%) .84
Permanent pacemaker 1 (5%) 1 (6%) 1.0
SAVR, Surgical aortic valve replacement; PAVR, percutaneous aortic valve replace-
ment.ardiovascular Surgery c Volume 137, Number 6 1433
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terizing patients with severe AS who did not undergo
SAVR.8-10,12 Patients were selected in these studies by ei-
ther searching echocardiographic laboratory databases8,10
or by means of a survey of patients referred for SAVR.9 In-
herently, these studies might have excluded patients not
referred for SAVR and occurred before the availability of
PAVR. Our study is the first to characterize and report out-
comes of patients screened for PAVR, thus including pa-
tients with severe symptomatic AS, many of whom would
probably not have been referred for SAVR otherwise. Of
the 92 patients screened, 20% could undergo conventional
surgical intervention with a good outcome (only 1 death at
2 months and no operative mortality) at our institution
with high surgical volume. This is in concurrence with exist-
ing data that show an association of surgeon and hospital
volume with surgical mortality.19,20
Past studies have shown that although BAV can result in
temporary relief of symptoms, restenosis is certain within 6
to 12 months.21-24 This led to clinical guidelines recom-
mending BAV as a reasonable bridge to surgical interven-
tion in hemodynamically unstable patients at high risk for
AVR or as a palliative procedure in patients with AS at
high risk for SAVR (class IIb indication).4 Patients under-
going BAV (n ¼ 30) had lower mortality compared with
patients not undergoing any intervention (33% vs 42%).
This was mainly due to 11 patients who could be bridged
to SAVR or PAVR. Patients undergoing BAV who could
not be bridged had a high mortality rate of 47% on fol-
low-up, which is similar to that seen in patients who had
no intervention. Most of these patients were waiting for
PAVR after undergoing BAV. With the advent of PAVR
and the rapid developments in this field, there has been a re-
surgence of interest in BAV procedures that otherwise offer
little long-term benefit. Future studies will help to define this
emerging role of BAV in bridging patients to PAVR.
Many patients with AS and heart failure have moderate-
to-severe MR. In our patient population 14 patients had at
least moderate MR, and 6 (42%) underwent BAV initially.
Two of these patients were subsequently bridged to PAVR.
The ongoing randomized study for PAVR excludes patients
with severe MR. Use of BAV in patients who are not surgi-
cal candidates in this population remains uncertain.
Our study shows that patients with severe symptomatic
AS who did not undergo aortic valve replacement had
a high mortality, which concurs with the existing data.4-8
Most of the deaths in this group occurred while patients
were in the process of being screened for PAVR or waiting
for the procedure. Our study shows that replacing the aortic
valve in these very sick elderly patients with severe symp-
tomatic AS improves survival. Undoubtedly, a multifaceted
management plan is required for successful management of
elderly patients with severe AS. However, it appears that de-
finitive treatment with valve replacement is imperative for1434 The Journal of Thoracic and Cardiovascular Sany plan to succeed. It is conceivable that wider availability
of PAVR, timely intervention, and earlier referral to centers
experienced in multidisciplinary treatment of high-risk pa-
tients with AS will result in better outcomes.
Although this study brought to light many more patients
with severe AS who could not be included in the previous
studies, there are potentially many more patients who were
not referred for PAVR, mainly because of the novelty of
the approach. There might be a selection bias in that this is
a single-center study from a tertiary care center with exper-
tise in valvular heart surgery. Despite this limitation, our
findings highlight the potential of new treatment paradigms
that will emerge with PAVR.
CONCLUSION
In summary, patients with advanced age, renal insuffi-
ciency, lung disease, previous cardiac surgeries, and poor
left ventricular function are referred for PAVR. Symptomatic
patients with severe AS have highmortality if aortic valve re-
placement is not feasible in a timely manner. Approximately
20% of the patients referred for PAVR could undergo surgi-
cal AVR with a good outcome. Patients managed with BAV
or without any intervention have unfavorable outcomes.
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